1. Proton-pump inhibitor use amongst patients with severe hypomagnesemia
- Author
-
Sherry Seah, Yen Kheng Tan, Kevin Teh, Wann Jia Loh, Pei Ting Tan, Leng Chuan Goh, Roy Debajyoti Malakar, Tar Choon Aw, Chin Shern Lau, Trishpal Dhalliwal, Swee Leng Kui, Jia Wen Kam, Joan Khoo, Tunn Lin Tay, Eberta Tan, Vanessa Au, Shui Boon Soh, Meifen Zhang, Thomas F. King, Linsey Gani, and Troy H. Puar
- Subjects
omeprazole ,magnesium ,chronic kidney disease ,drug adverse effects ,medication safety ,toxicity ,Therapeutics. Pharmacology ,RM1-950 - Abstract
Introduction: Long-term proton pump inhibitor (PPI) use has been associated with hypomagnesemia. It is unknown how frequently PPI use is implicated in patients with severe hypomagnesemia, and its clinical course or risk factors.Methods: All patients with severe hypomagnesemia from 2013 to 2016 in a tertiary center were assessed for likelihood of PPI-related hypomagnesemia using Naranjo algorithm, and we described the clinical course. The clinical characteristics of each case of PPI-related severe hypomagnesemia was compared with three controls on long-term PPI without hypomagnesemia, to assess for risk factors of developing severe hypomagnesemia.Results: Amongst 53,149 patients with serum magnesium measurements, 360 patients had severe hypomagnesemia (
- Published
- 2023
- Full Text
- View/download PDF